Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

KIT and mastocytosis.

Ken-Hong Lim1, Animesh Pardanani, Ayalew Tefferi

  • 1Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Acta Haematologica
|June 21, 2008
PubMed
Summary

Gain-of-function KIT mutations, particularly KITD816V, drive systemic mastocytosis (SM). Understanding these mutations is crucial for developing targeted therapies for SM, as current treatments are often suboptimal.

Related Concept Videos

Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

76
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
76

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.

Blood cancer journal·2026
Same author

ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.

American journal of hematology·2026
Same author

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.

American journal of hematology·2026
Same author

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia.

American journal of hematology·2026
Same author

<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients.

Haematologica·2026
Same author

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.

American journal of hematology·2026

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • KIT is a receptor tyrosine kinase vital for cell development and function.
  • KIT mutations, especially gain-of-function types, are linked to various cancers, including systemic mastocytosis (SM).
  • The KITD816V mutation is prevalent in SM, but its exact role in disease pathogenesis requires further elucidation.

Purpose of the Study:

  • To explore the role of KIT mutations in diseases.
  • To understand the pathogenetic contribution of KITD816V in systemic mastocytosis.
  • To highlight the need for targeted therapies for mutant KIT.

Main Methods:

  • Review of scientific literature on KIT mutations and associated diseases.
  • Analysis of the prevalence and clinical significance of KITD816V in systemic mastocytosis.
  • Discussion of current therapeutic strategies and the development of novel small molecule drugs targeting mutant KIT.

Main Results:

  • Gain-of-function KIT mutations are associated with hematologic malignancies like SM.
  • KITD816V is found in over 90% of SM cases meeting diagnostic criteria.
  • The precise pathogenetic role of KITD816V in SM remains incompletely understood.

Conclusions:

  • KIT mutations play a significant role in the development of systemic mastocytosis.
  • Targeting mutant KIT with small molecule drugs represents a promising therapeutic avenue for SM.
  • Further research is needed to fully understand the pathogenetic mechanisms and optimize treatment strategies for KIT-driven malignancies.

Related Experiment Videos